MA40067A - Sels de chlorhydrate de n-(cyanométhyl)-4-(2-(4-morpholinophénylamino)pyrimidin-4-yl)benzamide - Google Patents

Sels de chlorhydrate de n-(cyanométhyl)-4-(2-(4-morpholinophénylamino)pyrimidin-4-yl)benzamide

Info

Publication number
MA40067A
MA40067A MA040067A MA40067A MA40067A MA 40067 A MA40067 A MA 40067A MA 040067 A MA040067 A MA 040067A MA 40067 A MA40067 A MA 40067A MA 40067 A MA40067 A MA 40067A
Authority
MA
Morocco
Prior art keywords
morpholinophenylamino
cyanomethyl
pyrimidin
benzamide hydrochloride
hydrochloride salts
Prior art date
Application number
MA040067A
Other languages
English (en)
Inventor
Brandon H Brown
Ernest A Carra
Jeffrey N Hemenway
Henry Morrison
Troy Reynolds
Bing Shi
Dimitrios Stefanidis
Fang Wang
Matthew Robert Warr
James Andrew Whitney
Yan Xin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40067(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA40067A publication Critical patent/MA40067A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des nouvelles formes de sels stables de
MA040067A 2014-06-12 2015-06-11 Sels de chlorhydrate de n-(cyanométhyl)-4-(2-(4-morpholinophénylamino)pyrimidin-4-yl)benzamide MA40067A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12

Publications (1)

Publication Number Publication Date
MA40067A true MA40067A (fr) 2015-12-17

Family

ID=53674249

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040067A MA40067A (fr) 2014-06-12 2015-06-11 Sels de chlorhydrate de n-(cyanométhyl)-4-(2-(4-morpholinophénylamino)pyrimidin-4-yl)benzamide

Country Status (35)

Country Link
US (4) US9469613B2 (fr)
EP (3) EP3907219A1 (fr)
JP (5) JP6600649B2 (fr)
KR (1) KR101928225B1 (fr)
CN (2) CN106458929A (fr)
AP (1) AP2016009551A0 (fr)
AR (1) AR100818A1 (fr)
AU (1) AU2015274554B9 (fr)
BR (1) BR112016028749A2 (fr)
CA (1) CA2951883C (fr)
CR (1) CR20160575A (fr)
CU (1) CU20160183A7 (fr)
CY (1) CY1123604T1 (fr)
DK (1) DK3154950T3 (fr)
EA (1) EA032639B1 (fr)
EC (1) ECSP16093323A (fr)
ES (1) ES2822773T3 (fr)
FI (1) FIC20240025I1 (fr)
FR (1) FR24C1030I1 (fr)
HR (1) HRP20201492T1 (fr)
HU (2) HUE051360T2 (fr)
IL (3) IL249038B (fr)
LT (1) LT3154950T (fr)
MA (1) MA40067A (fr)
MX (3) MX2016016294A (fr)
NZ (1) NZ725966A (fr)
PH (1) PH12016502461A1 (fr)
PL (1) PL3154950T3 (fr)
PT (1) PT3154950T (fr)
RS (1) RS61065B1 (fr)
SG (2) SG11201610079VA (fr)
SI (1) SI3154950T1 (fr)
TW (3) TWI729644B (fr)
UY (1) UY36166A (fr)
WO (1) WO2015191846A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10245268B2 (en) 2016-08-10 2019-04-02 Sierra Oncology, Inc. Treatment of ACVR1-mediated diseases
CN115844894B (zh) * 2018-05-15 2024-08-06 江苏豪森药业集团有限公司 包含第三代小分子egfr抑制剂的药物组合物及其制备方法
CN113015527A (zh) 2018-08-21 2021-06-22 西拉肿瘤学公司 治疗骨髓纤维化的血小板计数诊断方法
EP3923948A4 (fr) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. Formes cristallines d'un inhibiteur de jak2
EP4376849A1 (fr) 2021-07-30 2024-06-05 GlaxoSmithKline LLC Biomarqueur et sélection de patient dans le traitement de la myélofibrose
EP4384181A2 (fr) 2021-08-10 2024-06-19 GlaxoSmithKline LLC Polythérapie à base de momélotinib
WO2023023473A1 (fr) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Méthodes d'utilisation de momélotinib pour traiter une maladie rénale chronique
WO2023152773A1 (fr) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Formes solides de sels de momélotinib et procédés améliorés pour la préparation de momélotinib

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
JP2004528295A (ja) 2001-01-30 2004-09-16 サイトピア ピーティワイ リミテッド キナーゼ阻害方法
JP4160401B2 (ja) 2001-03-29 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ−ｊｕｎｎ末端キナーゼ（ｊｎｋ）および他のタンパク質キナーゼのインヒビター
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
EP1427391B1 (fr) 2001-09-12 2008-07-09 ViRexx Medical Corporation Agent de phase solide d'occlusion vasculaire associe a un agent de liaison plaquettaire immobilise
CN100558715C (zh) 2002-05-23 2009-11-11 西托匹亚有限公司 蛋白激酶抑制剂
EP1546117A2 (fr) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase et leurs utilisations
WO2004041789A1 (fr) 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de proteines jak et autres proteines kinase
CA2506773A1 (fr) 2002-11-04 2004-05-21 Vertex Pharmaceuticals Incorporated Derives d'heteroaryle pyrimidine utilises comme inhibiteurs de jak (janus kinase)
JP2006508107A (ja) 2002-11-05 2006-03-09 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼのインヒビターとして有用な化合物
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
JP2007500179A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
HUE030839T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
BRPI0516597A (pt) 2004-10-13 2008-09-16 Wyeth Corp composto da fórmula
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
JP2009525337A (ja) 2006-01-30 2009-07-09 エクセリクシス， インク． Ｊａｋ−２調節因子としての４−アリール−２−アミノ−ピリミジン類又は４−アリール−２−アミノアルキル−ピリミジン類と使用方法
WO2007101232A2 (fr) 2006-02-28 2007-09-07 Cytopia Research Pty, Ltd. Inhibition de jak2 pour traiter l'hypertension artérielle pulmonaire
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
WO2008109943A1 (fr) 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Composés de phénylamino pyrimidine et utilisations de ces derniers
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
PT2200436E (pt) 2007-09-04 2015-04-29 Scripps Research Inst Pirimidinilaminas substituídas como inibidoras da proteína quinase
WO2009029998A1 (fr) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Composés rétrométaboliques
WO2009073575A2 (fr) 2007-11-30 2009-06-11 Oregon Health & Science University Procédés de traitement des troubles prolifératifs cellulaires induits
KR20110053347A (ko) 2008-08-05 2011-05-20 탈자진 인코포레이티드 탈라세미아를 치료하는 방법
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8580749B2 (en) 2009-06-05 2013-11-12 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
PL2578585T3 (pl) 2010-05-31 2017-01-31 Ono Pharmaceutical Co., Ltd. Pochodna purynonu jako inhibitor kinazy btk
SG10201509919UA (en) * 2010-12-03 2016-01-28 Ym Biosciences Australia Pty Treatment of jak2-mediated conditions
CN103533939A (zh) 2011-05-02 2014-01-22 澳大利亚Ym生物科学私人有限公司 多发性骨髓瘤治疗
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
WO2014051056A1 (fr) * 2012-09-28 2014-04-03 東レ株式会社 Cristaux de dérivé de glycine et leur utilisation pharmaceutique
CA2897814C (fr) 2013-01-09 2022-06-21 Concert Pharmaceuticals, Inc. Momelotinib deutere
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺

Also Published As

Publication number Publication date
TW202134236A (zh) 2021-09-16
TW201617323A (zh) 2016-05-16
AU2015274554A1 (en) 2016-11-24
CN110627728A (zh) 2019-12-31
EA032639B1 (ru) 2019-06-28
RS61065B1 (sr) 2020-12-31
USRE48285E1 (en) 2020-10-27
SI3154950T1 (sl) 2021-01-29
EP3154950B1 (fr) 2020-08-05
KR20170015496A (ko) 2017-02-08
MX2016016294A (es) 2017-09-01
JP7550205B2 (ja) 2024-09-12
PT3154950T (pt) 2020-10-09
WO2015191846A1 (fr) 2015-12-17
CU20160183A7 (es) 2017-05-10
FIC20240025I1 (fi) 2024-07-12
BR112016028749A2 (pt) 2017-08-22
TW202012378A (zh) 2020-04-01
US20150361050A1 (en) 2015-12-17
EP3154950A1 (fr) 2017-04-19
EP3907219A1 (fr) 2021-11-10
AU2015274554B9 (en) 2018-04-12
IL249038A0 (en) 2017-01-31
SG11201610079VA (en) 2016-12-29
FR24C1030I1 (fr) 2024-08-30
IL276948A (en) 2020-10-29
USRE49445E1 (en) 2023-03-07
PL3154950T3 (pl) 2021-01-25
AU2015274554B2 (en) 2018-02-15
AP2016009551A0 (en) 2016-11-30
JP2017517535A (ja) 2017-06-29
JP2018184486A (ja) 2018-11-22
JP2021107465A (ja) 2021-07-29
EP3719005A1 (fr) 2020-10-07
LT3154950T (lt) 2020-11-25
JP2020059759A (ja) 2020-04-16
PH12016502461A1 (en) 2017-03-06
TWI681954B (zh) 2020-01-11
CN106458929A (zh) 2017-02-22
DK3154950T3 (da) 2020-09-14
US9809559B2 (en) 2017-11-07
MX2019009564A (es) 2019-10-02
CY1123604T1 (el) 2022-03-24
JP6883560B2 (ja) 2021-06-09
ES2822773T3 (es) 2021-05-04
IL286442A (en) 2021-10-31
HUE051360T2 (hu) 2021-03-01
SG10201911925TA (en) 2020-01-30
JP2023021454A (ja) 2023-02-10
ECSP16093323A (es) 2017-01-31
NZ725966A (en) 2018-04-27
CR20160575A (es) 2017-01-20
HRP20201492T1 (hr) 2021-01-08
IL249038B (en) 2020-09-30
TWI729644B (zh) 2021-06-01
KR101928225B1 (ko) 2018-12-11
JP7198867B2 (ja) 2023-01-04
US9469613B2 (en) 2016-10-18
JP6840909B2 (ja) 2021-03-10
HUS2400025I1 (hu) 2024-08-28
US20160347719A1 (en) 2016-12-01
CA2951883A1 (fr) 2015-12-17
IL276948B (en) 2021-09-30
CA2951883C (fr) 2020-05-05
JP6600649B2 (ja) 2019-10-30
UY36166A (es) 2016-01-29
AR100818A1 (es) 2016-11-02
MX2022015558A (es) 2023-01-30
EA201692356A1 (ru) 2017-07-31

Similar Documents

Publication Publication Date Title
MA40067A (fr) Sels de chlorhydrate de n-(cyanométhyl)-4-(2-(4-morpholinophénylamino)pyrimidin-4-yl)benzamide
IL274488B1 (en) Crystal forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
HK1245770A1 (zh) 尿嘧啶化合物的新型結晶
IL249491A0 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4- Carboxamide
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
PH12015500795B1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
SG11201704431VA (en) Novel salt of fused pyrimidine compound and crystal thereof
MX2018000308A (es) Modificacion cristalina termodinamicamente estable de 2-cloro-3-(metilsulfanil)-n-(1-metil-1h-tetrazol-5-il)-4-(trifluo rometil)benzamida.
DOP2016000322A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida